Synergy between Celecoxib and Radiotherapy Results from Inhibition of Cyclooxygenase-2-Derived Prostaglandin E2, a Survival Factor for Tumor and Associated Vasculature

Cancer Research

Volumn 64, Issue 1, 2004, Pages 279-285

  Davis, Thomas W ^a   O'Neal, Janet M ^a   Pagel, Mark D ^a   Zweifel, Ben S ^a   Mehta, Pramod P ^a   Heuvelman, Deborah M ^a   Masferrer, Jaime L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN E2;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER RADIOTHERAPY; CONTRAST ENHANCEMENT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DISEASE MODELS, ANIMAL; HUMANS; ISOENZYMES; KINETICS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES; TIME FACTORS;

EID: 1642494834     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1168     Document Type: Article

References (51)

1. Furuta, Y., Hunter, N., Barkley, T., Jr., Hall, E., and Milas, L. Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res., 48: 3008-3013, 1988.
2. Furuta, Y., Hall, E. R., Sanduja, S., Barkley, T., Jr., and Milas, L. Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin. Cancer Res., 48: 3002-3007, 1988.
3. Bolten, W. W. Scientific rationale for specific inhibition of COX-2. J. Rheumatol., 51 (Suppl.): 2-7, 1998.
4. Houchen, C. W., Stenson, W. F., and Cohn, S. M. Disruption of cyclooxygenase-1 gene results in an impaired response to radiation injury. Am. J. Physiol. Gastrointest. Liver Physiol., 279: G858-G865, 2000.
5. Gaffney, D. K., Holden, J., Davis, M., Zempolich, K., Murphy, K. J., and Dodson, M. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 49: 1213-1217, 2001.
6. Steinauer, K. K., Gibbs, I., Ning, S., French, J. N., Armstrong, J., and Knox, S. J. Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int. J. Radiat. Oncol. Biol. Phys., 48: 325-328, 2000.
7. Fosslien, E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit. Rev. Clin. Lab. Sci., 37: 431-502, 2000.
8. Koki, A. T., Leahy, K. M., and Masferrer, J. L. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin. Investig. Drugs, 8: 1623-1638, 1999.
9. Masferrer, J. L., Leahy, K. M., Koki, A. T., Zweifel, B. S., Settle, S. L., Woemer, B. M., Edwards, D. A., Flickinger, A. G., Moore, R. J., and Seibert, K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res., 60: 1306-1311, 2000.
10. 2 production by suppressor monocytes in head and neck cancer patients. Ann. Surg., 196: 645-650, 1982.
11. Bennett, A., Charlier, E. M., McDonald, A. M., Simpson, J. S., Stamford, I. F., and Zebro, T. Prostaglandins and breast cancer. Lancet, 2: 624-626, 1977.
12. Bennett, A., Tacca, M. D., Stamford, I. F., and Zebro, T. Prostaglandins from tumours of human large bowel. Br. J. Cancer, 35: 881-884, 1977.
13. 2 and angiogenesis. Proc. Soc. Exp. Biol. Med., 172: 214-218, 1983.
14. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
15. Leahy, K. M., Koki, A. T., and Masferrer, J. L. Role of cyclooxygenases in angiogenesis. Curr. Med. Chem., 7: 1163-1170, 2000.
16. Leahy, K. M., Omberg, R. L., Wang, Y., Zweifel, B. S., Koki, A. T., and Masferrer, J. L. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res., 62: 625-631, 2002.
17. Masferrer, J. Approach to angiogenesis inhibition based on cyclooxygenase-2. Cancer J., 7 (Suppl. 3): S144-S150, 2001.
18. Williams, C. S., Tsujii, M., Reese, J., Dey, S. K., and DuBois, R. N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Investig., 105: 1589-1594, 2000.
19. Eisen, V., and Walker, D. I. Effect of ionizing radiation on prostaglandin-like activity in tissues. Br. J. Pharmacol., 57: 527-532, 1976.
20. Eisen, V., Walker, D. I., Binysh, S. G., and Tedder, R. S. Prostaglandins and complement changes in some conditions related to inflammation. Agents Actions, 2 (Suppl.): 99-108, 1977.
21. Eisen, V., and Walker, D. I. Effect of ionizing radiation on prostaglandin 15-OH-dehydrogenase (PGDH). Br. J. Pharmacol., 62: 461P, 1978.
22. Eldor, A., Vlodavsky, I., HyAm, E., Atzmon, R., and Fuks, Z. The effect of radiation on prostacyclin (PGI2) production by cultured endothelial cells. Prostaglandins, 25: 263-279, 1983.
23. Hahn, G. L., Menconi, M. J., Cahill, M., and Polgar, P. The influence of γ radiation on arachidonic acid release and prostacyclin synthesis. Prostaglandins, 25: 783-791, 1983.
24. Schneidkraut, M. J., Kot, P. A., Ramwell, P. W., and Rose, J. C. Regional release of cyclooxygenase products after radiation exposure of the rat. J. Appl. Physiol., 61: 1264-1269, 1986.
25. Teicher, B. A., Korbut, T. T., Menon, K., Holden, S. A., and Ara, G. Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies. Cancer Chemother. Pharmacol., 33: 515-522, 1994.
26. Weshler, Z., Raz, A., Rosenmann, E., Weinman, E., Biran, S., Fuks, Z., and Eldor, A. The effects of ionizing irradiation on production of thromboxane and prostacyclin by the isolated perfused rat kidney. In Vivo, 2: 289-293. 1988.
27. Lognonne, J. L., Ducousso, R., Rocquet, G., and Kergonou. J. F. Influence of whole-body γ irradiation upon arachidonic acid metabolism in rat platelets. Biochimie (Paris), 67: 1015-1021, 1985.
28. Fosslien, E. Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann. Clin. Lab. Sci., 31: 325-348. 2001.
29. 2 increases survival of murine intestinal stem cells when given before photon radiation. Radiat. Res., 96: 393-398, 1983.
30. 1 analog, misoprostol: a placebo controlled double blind clinical trial. Adv. Exp. Med. Biol., 400B: 811-818, 1997.
31. Miller, R. C., Lanasa, P., and Hanson, W. R. Misoprostol-induced radioprotection of Syrian hamster embryo cells in utero from cell death and oncogenic transformation. Radiat. Res., 139: 109-114, 1994.
32. Miller, R. C., Lanasa, P., and Hanson, W. R. Misoprostol: a potent cytotoxic and oncogenic radioprotector. Adv. Exp. Med. Biol., 400B: 861-864, 1997.
33. Riehl, T., Cohn, S., Tessner, T., Schloemann, S., and Stenson, W. F. Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism. Gastroenterology, 118: 1106-1116, 2000.
34. van Buul, P. P., Duyn-Goedhart, A., de Rooij, D. G., and Sankaranarayanan, K. Differential radioprotective effects of misoprostol in DNA repair-proficient and -deficient or radiosensitive cell systems. Int. J. Radiat. Biol., 71: 259-264, 1997.
35. 2 analogue misoprostol in DNA repair-proficient and -deficient rodent cell systems. Radiat. Res., 152: 398-403, 1999.
36. 2 (nocloprost) on the radiation response of human normal fibroblasts and colon adenocarcinoma cells. Radiat. Res., 135: 88-92, 1993.
37. Kumar, K. S., Srinivasan, V., Palazzolo, D., Kendrick, J. M., and Clark, E. P. Synergistic protection of irradiated mice by a combination of iloprost and misoprostol. Adv. Exp. Med. Biol., 400B: 831-839, 1997.
38. Duffy, C. P., Elliott, C. J., O'Connor, R. A., Heenan, M. M., Coyle, S., Cleary, I. M., Kavanagh, K., Verhaegen, S., O'Loughlin, C. M., NicAmhlaoibh, R., and Clynes, M. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur. J. Cancer, 34: 1250-1259. 1998.
39. Davis, T. W., Hunter, N., Trifan, O. C., Milas, L., and Masferrer, J. L. COX-2 inhibitors as radiosensitizing agents for cancer therapy. Am. J. Clin. Oncol., 26: S58-S61, 2003.
40. Kishi, K., Petersen, S., Petersen, C., Hunter, N., Mason, K., Masferrer, J. L., Tofilon, P. J., and Milas, L. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res., 60: 1326-1331, 2000.
41. Milas, L., Kishi, K., Hunter, N., Mason, K., Masferrer, J. L., and Tofilon, P. J. Enhancement of tumor response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl. Cancer Inst. (Bethesda), 91: 1501-1504, 1999.
42. Milas, L., Mason, K. A., Crane, C. H., Liao, Z., and Masferrer, J. Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme. Oncology (Huntingt), 17: 15-24, 2003.
43. Milas, L. Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis. Am. J. Clin. Oncol., 26: S66-S69, 2003.
44. Koki, A. T., Khan, N. K., Woemer, B. M., Seibert, K., Harmon, J. L., Dannenberg, A. J., Soslow, R. A., and Masferrer, J. L. Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers. Prostaglandins Leukotrienes Essent. Fatty Acids, 66: 13-18, 2002.
45. Zweifel, B. S., Davis, T. W., Ornberg, R. L., and Masferrer, J. L. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res., 62: 6706-6711, 2002.
46. Trifan, O. C., Durham, W. F., Salazar, V. S., Horton, J., Levine, B. D., Zweifel, B. S., Davis, T. W., and Masferrer, J. L. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res., 62: 5778-5784, 2002.
47. Petersen, C., Petersen, S., Milas, L., Lang, F. F., and Tofilon, P. J. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin. Cancer Res., 6: 2513-2520, 2000.
48. Dicker, A. P., Williams, T. L., and Grant, D. S. Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am. J. Clin. Oncol., 24: 438-442, 2001.
49. Garcia-Barros, M., Paris, F., Cordon-Cardo, C., Lyden, D., Rafii, S., Haimovitz-Friedman, A., Fuks, Z., and Kolesnick, R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science (Wash. DC), 300: 1155-1159, 2003.
50. Wachsberger, P., Burd, R., and Dicker, A. P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin. Cancer Res., 9: 1957-1971, 2003.
51. Cohn, S. M., Schloemann, S., Tessner, T., Seibert, K., and Stenson, W. F. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J. Clin. Investig., 99: 1367-1379, 1997.